Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Maria Kalamvoki · UNIVERSITY OF KANSAS MEDICAL CENTER · 2020 · $420,750 — ABSTRACT COronaVIrus Disease 2019 (COVID-19) is caused by a human coronavirus, SARS-CoV-2. This virus caused a large outbreak in China that was associated with a high human-to-human transmission rate and mortality and subsequently led to a pandemic in the human population. SARS-CoV-2 is member of th…
JOSEPH VINCENT BONVENTRE · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $251,531 — Abstract Coronavirus disease 2019 (COVID-19) has reached pandemic proportions. Pulmonary and kidney disease are highly prevalent serious consequences of infection with SARS-CoV-2. Kidney Injury Molecule-1 (KIM-1) was identified by Drs Bonventre and Ichimura as the most upregulated protein in the inj…
Steffen Mueller · CODAGENIX, INC. · 2020 · $1,716,496 — There is a clear unmet need for a vaccine against the ongoing epidemic of coronavirus disease 2019 (COVID19) caused by SARS-CoV-2. SARS-CoV-2 was initially detected in the Hubei Province of China late in 2019. SARS-CoV-2 is highly contagious (R0 of 1.4-3.9, greater than seasonal influenza), and pres…
RUSSELL R BROADDUS · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $162,000 — The 2019 novel coronavirus, SARS-CoV-2 causes COVID-19, a pandemic viral disease. This disease has resulted in world-wide fatalities, particularly in patients with cardiovascular disease, and arterial hypertension. As of June 2020, close to 6.6 million cases and death of 393,000 were reported worldw…
Peter B. Gilbert · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $1,414,274 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the first COVID-19 vaccine efficacy trial “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evalua…
Susan Daniel · CORNELL UNIVERSITY · 2020 · $229,985 — Project Summary / Abstract Enveloped viruses access their host cells by binding to receptors on the plasma membrane and then undergoing fusion with the host membrane. Both binding and fusion are mediated by a specific viral “spike” protein that is typically primed for fusion activation by proteolyti…
Ralph S Baric · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $3,974,612 — Abstract. The UNC Center for Excellence in SARS-CoV2 Serologic Research uses basic and applied research strategies to improve our understanding of the molecular and cellular mechanisms driving serological and humoral immune responses after SARS-CoV2 infection. Our overall goals are to 1) characteriz…
Irina Leonidovna Grigorova · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $513,210 — Various nanoparticles (NPs) have been used for delivery of small antigens, which have limited viral mimic features and are more efficacious than soluble antigens in stimulating B-cell immunity. However, these traditional NPs lack characteristics of virus “spiky capsid protein peplomer”, e.g. spiky a…
Madepalli Krishnappa Lakshmana · FLORIDA INTERNATIONAL UNIVERSITY · 2020 · $195,353 — PROJECT ABSTRACT Airway epithelial cells or AECs orchestrate the pulmonary immune responses to airborne viral infections and drive the successful resolution of infection. Among the immediate early responders that set the tone for innate immune response, we have identified that as early as half-an-ho…
Erica Ollmann Saphire · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2020 · $2,688,763 — ABSTRACT We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike protein contributed by a range of large and small companies and academic labs on mult…
JAMES M OLSON · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $176,000 — We are proposing work that will address the fundamental question of whether or not the SARS-CoV-2 Spike protein, the basis of many leading COVID19 vaccine approaches, is sufficiently antigenic to elicit neutralizing antibody responses in pediatric patients undergoing chemotherapy. We will immunize c…
Peter Palese · ROCKEFELLER UNIVERSITY · 2020 · $654,116 — Abstract Given the uncontrolled spread of SARS-CoV-2 and the devastating impact on public health, therapeutic interventions are urgently needed for disease control. Indeed, several biotech and academic groups are currently focusing their efforts on the isolation and clinical development of monoclona…
Kristina De Paris · DUKE UNIVERSITY · 2020 · $1,227,827 — ABSTRACT The emergence of the highly-transmissible novel coronavirus SARS-CoV2 has led to a global pandemic of severe respiratory disease. While elderly individuals and adults with co-morbidities are high risk populations, coronavirus disease (COVID-19) can occur in individuals across all age groups…
Robert A Burne · UNIVERSITY OF FLORIDA · 2020 · $215,292 — Abstract/Summary Commensal oral streptococci are the most abundant bacteria in the biofilms that colonize the hard and soft tissues of the human oral cavity and many areas of the nasopharynx. These health-associated bacteria employ multiple diverse adhesion strategies and produce a spectrum of compo…
Michael S Kay · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2020 · $429,481 — Project Summary The 21st century has seen the emergence of multiple lethal human coronaviruses (SARS-CoV, MERS-CoV, and now SARS-CoV-2). There is an urgent need for therapeutic options to combat the current and inevitable future SARS-like pandemics. Coronaviruses infect cells using a conserved entr…
Neville Sanjana · NEW YORK GENOME CENTER · 2020 · $518,550 — PROJECT SUMMARY The COVID-19 pandemic has taken the lives of nearly 500,000 people worldwide in the span of a few months. Recently, a novel isolate of the SARS-CoV-2 virus carrying a point mutation in the Spike protein (D614G) has emerged and rapidly surpassed others in prevalence, including the or…
Alexis Noel Ross · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2020 · $29,520 — PROJECT SUMMARY/ABSTRACT The mechanisms that control hepatic stellate cell (HSC) migration during liver development and regeneration are not well understood. This knowledge gap has hindered the generation of new therapies and the improvement of patient outcome for various developmental disorders su…
Galit Alter · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $391,727 — Since 2002, several coronaviruses have emerged able to cause severe respiratory disease, however no vaccine is available to prevent these rapidly spreading pathogens. Vaccine design has specifically lagged due to our lack of understanding of the correlates of immunity against these pathogens. Both c…
JULIE M. OVERBAUGH · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $355,912 — ABSTRACT The greatest hope for an end to the COVID19 pandemic caused by SARS-CoV-2 is a vaccine and/or antibody therapy. At this point, we know little about protective immunity to SARS-CoV-2, including which epitopes are the major target of the antibody response to this virus and whether antibodies…
Grace M Aldrovandi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $1,225,641 — Abstract The novel SARS-CoV-2 is the cause of the coronavirus (CoV) disease (COVID-19) outbreak that currently pose a serious pandemic threat to public health. A safe vaccine that rapidly induces long-lasting virus-specific immune responses is urgently needed. The CoV spike (S) protein, a characteri…